Research programme: cachexia therapeutic - Tensive Controls
Latest Information Update: 22 Jul 2016
At a glance
- Originator Tensive Controls
- Class Melanocortins; Peptides
- Mechanism of Action Melanocortin receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cachexia